RNS Number : 2612F Renalytix PLC 06 July 2023 Renalytix plc ("Renalytix" or the "Company") Grant of Share Options LONDON and SALT LAKE CITY - July 6, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled
LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the
RNS Number : 7155E Renalytix PLC 03 July 2023 Renalytix plc ("Renalytix" or the "Company") Directorate Change Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors LONDON and SALT LAKE CITY - July 3, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the
RNS Number : 5264E Renalytix PLC 30 June 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. Renalytix plc ("Renalytix" or the "Company") FDA Approves KidneyIntelX.dkd™ FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline
Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the Leading Cause of End Stage Kidney Disease in the United States LONDON and SALT LAKE CITY, June 29, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX)
Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patients LONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE:
RNS Number : 7716C Renalytix PLC 15 June 2023 Renalytix plc ("Renalytix" or the "Company") KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences Four new data presentations, including late breaking clinical study data,
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
RNS Number : 1817C Renalytix PLC 09 June 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023 LONDON and SALT LAKE CITY , June 9, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in
RNS Number : 1562C Renalytix PLC 08 June 2023 Renalytix plc ("Renalytix" or the "Company") Result of General Meeting LONDON and SALT LAKE CITY , June 8, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting (" GM ") held earlier today all resolutions
